The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

For patients with migraine, the clinical benefits of propranolol, a beta-blocker medication, may extend beyond just migraine ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of ...

A rapid blood test could speed treatment for people who’ve suffered a stroke related to brain bleeding, a new study sa ...

Women's pain is often misdiagnosed or ignored. But what's being done about it? We asked women and MDs to weigh in on.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator ...

Red light therapy is increasingly viewed as a promising treatment for wrinkles, acne, psoriasis, scars and sun-damaged skin, and as a supportive therapy for some kinds of cancer. But does red light ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

AbbVie Inc . (NYSE:ABBV) delivered strong financial results for Q4 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.16, compared to the forecast of $2.06. The company ...